- Testing of insulin stability for permanently implanted delivery system – device was to be refilled every 6 months. Collaboration with an insulin producer to test possible formulations was key.
- Testing of other drug formulations (primarily pain medication) for use in a constant flow temporarily implanted delivery system in development was needed.
- Testing of other drug formulations (primarily pain medication and AIDS treatment cocktails) for use in the existing external delivery system was also needed.
- Analytical methodology was based on published methods from the USP and/or published research articles. These methods were tested and modified based on in lab results to produce a consistent test result on drug and other formulation component composition.
- The Lucid team was able to provide expertise in developing analytical testing protocols, a very specific field.
- Drug compatibility with delivery systems is complex – often impacted by other constituents in the formulation.
Expanded use of the system opens up more treatment markets for the company, particularly for treatments that have a low patient compliance or benefit from a continuous influx of medication rather than dosed systems.
The implantable insulin pump is in clinical trials. The external pump has a version that is called the “general medication pump” and is used to deliver hypertension medication. Other drug constituents are under investigation.